CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine

Vaccine

Volumn 26, Issue 9, 2008, Pages 1243-1252

  Eliasson, Dubravka Grdic ^a   Bakkouri, Karim El ^b   Schön, Karin ^a   Ramne, Anna ^c   Festjens, Els ^b   Löwenadler, Björn ^d   Fiers, Walter ^b   Saelens, Xavier ^b   Lycke, Nils ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b GHENT UNIVERSITY   (Belgium)

^c BIOVITRUM AB   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Antigens peptides epitopes; IgA immunity; Immunomodulation; Influenza A virus; Mucosa; Mucosal vaccination; Rodent; Spleen and lymph nodes; Targeted adjuvants

Indexed keywords

ADJUVANT; CTA1 M2E DD ADJUVANT; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX PROTEIN; MATRIX PROTEIN 2; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INFLUENZA VIRUS A; MALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; TANDEM REPEAT; TREATMENT RESPONSE; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CHOLERA TOXIN; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MALE; MICE; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; REASSORTANT VIRUSES; RECOMBINANT FUSION PROTEINS; VIRAL MATRIX PROTEINS;

EID: 39149131018     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.027     Document Type: Article

References (63)

1. Levine M.M., and Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 5 5 (2004) 460-464
2. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 2 (2006) 148-158
3. Nichol K.L., and Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 194 Suppl. 2 (2006) S111-S118
4. Maassab H.F., and Bryant M.L. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 9 4 (1999) 237-244
5. Abramowicz M. FluMist: an intranasal live influenza vaccine. Med Lett Drugs Ther 45 1163 (2003) 65-66
6. Bardiya N., and Bae J.H. Influenza vaccines: recent advances in production technologies. Appl Microbiol Biotechnol 67 3 (2005) 299-305
7. Waldman R.H., Wood S.H., Torres E.J., and Small Jr. P.A. Influenza antibody response following aerosal administration of inactivated virus. Am J Epidemiol 91 6 (1970) 574-585
8. Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24 3 (2006) 254-262
9. Stephenson I., Zambon M.C., Rudin A., Colegate A., Podda A., Bugarini R., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80 10 (2006) 4962-4970
10. Mizuno D., Ide-Kurihara M., Ichinomiya T., Kubo I., and Kido H. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J Immunol 176 2 (2006) 1122-1130
11. Joseph A., Itskovitz-Cooper N., Samira S., Flasterstein O., Eliyahu H., Simberg D., et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 24 18 (2006) 3990-4006
12. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22 23-24 (2004) 2993-3003
13. De Filette M., Ramne A., Birkett A., Lycke N., Lowenadler B., Min Jou W., et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24 5 (2006) 544-551
14. Beyer W.E., Palache A.M., de Jong J.C., and Osterhaus A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20 9-10 (2002) 1340-1353
15. Boyce T.G., Gruber W.C., Coleman-Dockery S.D., Sannella E.C., Reed G.W., Wolff M., et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 18 1-2 (1999) 82-88
16. Boyce T.G., Hsu H.H., Sannella E.C., Coleman-Dockery S.D., Baylis E., Zhu Y., et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19 2-3 (2000) 217-226
17. Clements M.L., and Murphy B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 23 1 (1986) 66-72
18. Gluck R., Mischler R., Durrer P., Furer E., Lang A.B., Herzog C., et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 181 3 (2000) 1129-1132
19. Kasel J.A., Hume E.B., Fulk R.V., Togo Y., Huber M., and Hornick R.B. Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine. J Immunol 102 3 (1969) 555-562
20. Kendal A.P., Snyder R., and Garrison P.J. Validation of cold chain procedures suitable for distribution of vaccines by public health programs in the USA. Vaccine 15 12-13 (1997) 1459-1465
21. Billaud J.N., Peterson D., Barr M., Chen A., Sallberg M., Garduno F., et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol 79 21 (2005) 13656-13666
22. Kaiser J. A one-size-fits-all flu vaccine?. Science 312 5772 (2006) 380-382
23. Gerhard W., Mozdzanowska K., and Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 12 4 (2006) 569-574
24. Frace A.M., Klimov A.I., Rowe T., Black R.A., and Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17 18 (1999) 2237-2244
25. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 10 (1999) 1157-1163
26. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., and Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13 15 (1995) 1399-1402
27. Liu W., Zou P., Ding J., Lu Y., and Chen Y.H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 7 2 (2005) 171-177
28. Gianfrani C., Oseroff C., Sidney J., Chesnut R.W., and Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol 61 5 (2000) 438-452
29. Fiers W., Neirynck S., Deroo T., Saelens X., and Jou W.M. Soluble recombinant influenza vaccines. Philos Trans R Soc Lond B Biol Sci 356 1416 (2001) 1961-1963
30. Zou P., Liu W., and Chen Y.H. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharmacol 5 4 (2005) 631-635
31. Zhang M., Zharikova D., Mozdzanowska K., Otvos L., and Gerhard W. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus. Mol Immunol 43 14 (2006) 2195-2206
32. Fiers W., De Filette M., Birkett A., Neirynck S., and Min Jou W. A "universal" human influenza A vaccine. Virus Res. 103 1-2 (2004) 173-176
33. Agren L.C., Ekman L., Lowenadler B., and Lycke N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 158 8 (1997) 3936-3946
34. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350 9 (2004) 896-903
35. Eriksson A.M., Schon K.M., and Lycke N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 173 5 (2004) 3310-3319
36. Simmons C.P., Mastroeni P., Fowler R., Ghaem-maghami M., Lycke N., Pizza M., et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 163 12 (1999) 6502-6510
37. Leclerc C., Lo-Man R., Charbit A., Martineau P., Clement J.M., and Hofnung M. Immunogenicity of viral B- and T-cell epitopes expressed in recombinant bacterial proteins. Int Rev Immunol 11 2 (1994) 123-132
38. Theisen D.M., Bouche F.B., El Kasmi K.C., von der Ahe I., Ammerlaan W., Demotz S., et al. Differential antigenicity of recombinant polyepitope-antigens based on loop- and helix-forming B and T cell epitopes. J Immunol Methods 242 1-2 (2000) 145-157
39. Grdic D., Smith R., Donachie A., Kjerrulf M., Hornquist E., Mowat A., et al. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action. Eur J Immunol 29 6 (1999) 1774-1784
40. Zheng B., Graham F.L., Johnson D.C., Hanke T., McDermott M.R., and Prevec L. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 11 12 (1993) 1191-1198
41. Yankai Z., Rong Y., Yi H., Wentao L., Rongyue C., Ming Y., et al. Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Biochem Biophys Res Commun 345 4 (2006) 1365-1371
42. Kjerrulf M., Lowenadler B., Svanholm C., and Lycke N. Tandem repeats of T helper epitopes enhance immunogenicity of fusion proteins by promoting processing and presentation. Mol Immunol 34 8-9 (1997) 599-608
43. Stohr K. Avian influenza and pandemics-research needs and opportunities. N Engl J Med 352 4 (2005) 405-407
44. Clements M.L., Betts R.F., Tierney E.L., and Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24 1 (1986) 157-160
45. Tumpey T.M., Renshaw M., Clements J.D., and Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75 11 (2001) 5141-5150
46. Jameson J., Cruz J., and Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 72 11 (1998) 8682-8689
47. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos Jr. L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21 19-20 (2003) 2616-2626
48. McMichael A.J., Gotch F.M., Noble G.R., and Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 309 1 (1983) 13-17
49. Ulmer J.B., Fu T.M., Deck R.R., Friedman A., Guan L., DeWitt C., et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72 7 (1998) 5648-5653
50. Tamura S., Miyata K., Matsuo K., Asanuma H., Takahashi H., Nakajima K., et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 156 10 (1996) 3892-3900
51. Mozdzanowska K., Furchner M., Zharikova D., Feng J., and Gerhard W. Roles of CD4+ T-cell-independent and dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J Virol 79 10 (2005) 5943-5951
52. Liang S., Mozdzanowska K., Palladino G., and Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 152 4 (1994) 1653-1661
53. Epstein S.L., Stack A., Misplon J.A., Lo C.Y., Mostowski H., Bennink J., et al. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int Immunol 12 1 (2000) 91-101
54. Macaulay A.E., DeKruyff R.H., and Umetsu D.T. Antigen-primed T cells from B cell-deficient JHD mice fail to provide B cell help. J Immunol 160 4 (1998) 1694-1700
55. Akhiani A.A., Stensson A., Schon K., and Lycke N. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand J Immunol 63 2 (2006) 97-105
56. Zharikova D., Mozdzanowska K., Feng J., Zhang M., and Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 79 11 (2005) 6644-6654
57. Claas E.C., and Osterhaus A.D. New clues to the emergence of flu pandemics. Nat Med 4 10 (1998) 1122-1123
58. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3 (2006) 102
59. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337 1 (2005) 149-161
60. Liu W., and Chen Y.H. High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol 35 2 (2005) 505-514
61. Black R.A., Rota P.A., Gorodkova N., Klenk H.D., and Kendal A.P. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 74 Pt 1 (1993) 143-146
62. Liu W., Li H., and Chen Y.H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 35 2 (2003) 141-146
63. Asahi-Ozaki Y., Itamura S., Ichinohe T., Strong P., Tamura S., Takahashi H., et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 8 12-13 (2006) 2706-2714